Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway

Imatinib (IM), as first inhibitor of the oncogenic tyrosine kinase BCR-ABL, has been widely used to treat chronic myeloid leukemia (CML) for decades in clinic. However, resistance to IM usually occurs in CML patients. The bone marrow (BM), as the predominant microenvironment of CML, secretes an abun...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Front Pharmacol
Hoofdauteurs: Zhang, Xiaobo, Liu, Yicheng, Lu, Lu, Huang, Shaoliang, Ding, Youxiang, Zhang, Yi, Guo, Qinglong, Li, Zhiyu, Zhao, Li
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Frontiers Media S.A. 2017
Onderwerpen:
Pharmacology
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5554535/
https://ncbi.nlm.nih.gov/pubmed/28848440
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00526
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items